• The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.

• Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

• Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of budesonide foam in subjects with active mild to moderate proctitis or proctosigmoiditis.

• The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of certolizumab pegol treatment in pediatric patients, aged 6 to 17, with moderately to severe active Crohn's disease. The target enrollment is 160 patients.

• Double-blind, randomized, multicenter, placebo-controlled study The purpose of this study is to evaluate the efficacy and safety of HMPL-004 in patients with active moderate Crohn's Disease,compared with placebo.

Adult patients that have had at least one episode of a diverticulitus attack in the last 36 months will be placed on a drug that may help patient symptoms.

The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis

(grade 0 on the Hetzel and Dent classification or grade 0 on the

Histological Features of Reflux Esophagitis scale) during the short-term double-blind treatment phase

• The purpose of the study is to evaluate the pharmacokinetics, pharmacodynamics and safety of rabeprazole after single and multiple daily administration in infants between the ages of 1 and 11 months, inclusive, with GERD.

•  The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).